Prostate Cancer Diagnostics and Treatment Market

Prostate Cancer Diagnostics and Treatment Market is expected to grow at a CAGR of 6.5% during the forecast period and the market size is expected to reach nearly USD 14.92 Bn by 2032.

Prostate Cancer Diagnostics and Treatment Market Overview:

One of the most common types of cancer is prostate cancer. Many prostate cancers are slow-growing and limited to the prostate gland, where they are unlikely to cause substantial harm. The majority of prostate malignancies are discovered through screening. Early prostate tumours rarely generate symptoms; however, symptoms caused by more advanced tumours can lead to their discovery.

To know about the Research Methodology :- Request Free Sample Report

Prostate Cancer Diagnostics and Treatment Market Dynamics:

Rising cases of Prostate Cancer worldwide is expected to majorly drive the market growth during forecast period.

One of the key factors driving demand for diagnostic tools is the rising prevalence of prostate cancer. According to the National Cancer Institute, around 174,650 new cases of cancer were identified in the United States in 2025. The primary drivers fuelling the market in the forecast period are increased attention on the illness burden and increased knowledge about the disease. Diagnostics for prostate cancer are critical for early identification and effective therapy of the illness. Prostate cancer is becoming more common, the geriatric population is growing, there are more investments in the field of prostate cancer diagnostics, and there is a growing awareness of the disease's early diagnosis. The Australian government and the Movember Foundation announced a partnership to fight prostate cancer in 2021, spending AUD 12 million in ground-breaking new research teams dedicated to undertaking life-saving prostate cancer research and reducing the number of fatalities caused by the disease.

During the forecast period, technological developments in diagnostic tests are projected to boost market growth even further. Researchers are currently studying the use of Artificial Intelligence (AI) to identify prostate cancer, according to the National Cancer Institute. Artificial intelligence (AI) is used to identify questionable spots identified during an MRI scan that require biopsies to confirm the presence of malignant cells. Another factor that is expected to fuel the growth of the prostate cancer diagnostics market in the near future is the increasing number of new market entrants.

The report has profiled nineteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Prostate Cancer Diagnostics and Treatment Market Segment Analysis:

The Prostate Cancer Diagnostics and Treatment Market is segmented on the basis of Type, Diagnosis and Treatment.

Based on Diagnosis, the Transrectal Ultrasound segment is anticipated to dominate the global market during the forecast period. The Transrectal ultrasound (TRUS) guided biopsy is another popular diagnostic method for prostate cancer that is still regarded as a feasible option. It is rapid and convenient for the provider, with a method that most urologists are familiar with and a low risk of urine retention. TRUS is a good choice with clinical benefits for patients who cannot have MRI procedures owing to claustrophobia, metal implants, or a lack of insurance coverage. The TRUS biopsy, which is the most popular and useful alternative transperineal method, has been endorsed by the American Urology Association and the European Association of Urology in recent years. Patients with related disorders are frequently treated with TURS biopsy, which has a significant advantage over other treatments. As a result, it is widely known and recognised .

In 2025, PCA3 held the largest market share in diagnostic testing. It's a biomarker that can help improve the accuracy of a prostate cancer diagnosis. Due to its relatively high sensitivity and specificity during diagnostic procedures, the biomarker is recommended.

Based on Treatment, the Therapeutics segment is expected to hold dominant market share by 2032. The segment is further divided into Hormonal Therapy, Chemotherapy and Other Treatments. Hormone therapy is a medication that prevents your body from manufacturing testosterone, the male hormone. Testosterone is required for prostate cancer cells to proliferate. Cancer cells may die or develop more slowly if their testosterone supply is cut off. In the year 2025, the hormone therapy sector dominated the market, accounting for 31.65% of the total market share. The rise in prostate cancer prevalence, an increase in demand for hormone therapy, promising pipeline medications, and the evolving treatment of prostate cancer treatment are all contributing to this trend. Hormone therapy is occasionally used before radiation therapy to treat prostate cancer that hasn't spread. It aids in the reduction of tumour size and improves the efficiency of radiation therapy.

Prostate Cancer Diagnostics and Treatment Market Regional Insights:

North America is expected to account for larger market share during forecast years.

Owing to factors such as rising prostate cancer prevalence, more awareness, and more research and development in this region, North America is expected to dominate the market share. According to the American Cancer Society, there were estimated to be 164,690 new prostate cancer cases and 29,430 deaths in the United States in 2025. The market dominance is owing to the higher acceptance of advanced technologies, well-established healthcare diagnostic facilities, the surging incidence of prostate cancer, and the enactment of numerous initiatives for raising awareness about the disease in the region.

APAC is expected to witness lucrative growth during forecast period.

Due to rising knowledge of prostate cancer treatment and adoption of prostate cancer treatment products, Asia-Pacific delivers the attractive potential for key players in the prostate cancer treatment market. Furthermore, developments in healthcare infrastructure, an increase in the number of hospitals with superior medical facilities, a growing R&D sector, increased healthcare reforms, and technical breakthroughs in the field of healthcare all contribute to market growth. Other factors driving the growth of the prostate cancer treatment market in Asia-Pacific include leading manufacturers' increased focus on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, a large population base, and high disposable incomes.

Recent Industry Developments (2025–2026)

The report also helps in understanding Global Prostate Cancer Diagnostics and Treatment Market dynamics, structure by analyzing the market segments and project the Global Prostate Cancer Diagnostics and Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Prostate Cancer Diagnostics and Treatment Market make the report investor’s guide.

Prostate Cancer Diagnostics and Treatment Market Scope: Inquire before buying

Prostate Cancer Diagnostics and Treatment Market By Region:

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Key Players / Competitors Profiles Covered in Brief in Global Prostate Cancer Diagnostics and Treatment Market Report in Strategic Perspective:

1. Astellas Pharma
2. Pfizer
3. Johnson & Johnson
4. Bayer
5. Novartis
6. AstraZeneca
7. Sanofi
8. Merck & Co.
9. F. Hoffmann-La Roche Ltd.
10. GE HealthCare
11. Siemens Healthineers
12. Thermo Fisher Scientific
13. Lantheus Holdings
14. Telix Pharmaceuticals
15. Myriad Genetics
16. Exact Sciences
17. bioMérieux
18. Fujifilm Holdings
19. Exelixis
20. Ipsen Pharma
21. Candel Therapeutics
22. Clarity Pharmaceuticals
23. Janux Therapeutics
24. Sumitomo Pharma
25. AbbVie